AxoGen, Inc (AXGN) SVP Sells $434,700.00 in Stock

AxoGen, Inc (NASDAQ:AXGN) SVP Shawn F. Mccarrey sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, May 16th. The shares were sold at an average price of $43.47, for a total value of $434,700.00. Following the transaction, the senior vice president now owns 33,057 shares of the company’s stock, valued at $1,436,987.79. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

AXGN stock opened at $43.95 on Monday. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.32 and a quick ratio of 2.81. AxoGen, Inc has a 1 year low of $13.95 and a 1 year high of $46.00.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Monday, April 30th. The medical equipment provider reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.11). The company had revenue of $17.30 million for the quarter, compared to analyst estimates of $17.16 million. AxoGen had a negative return on equity of 61.66% and a negative net margin of 18.83%. The company’s quarterly revenue was up 41.8% compared to the same quarter last year. analysts anticipate that AxoGen, Inc will post -0.38 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of AXGN. William Blair Investment Management LLC acquired a new stake in shares of AxoGen during the 4th quarter worth about $5,081,000. BlackRock Inc. raised its position in shares of AxoGen by 29.7% during the 4th quarter. BlackRock Inc. now owns 1,785,891 shares of the medical equipment provider’s stock worth $50,540,000 after acquiring an additional 408,596 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of AxoGen by 63.5% during the 4th quarter. Renaissance Technologies LLC now owns 657,800 shares of the medical equipment provider’s stock worth $18,616,000 after acquiring an additional 255,400 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in shares of AxoGen during the 4th quarter worth about $662,000. Finally, Proficio Capital Partners LLC raised its position in shares of AxoGen by 5.6% during the 4th quarter. Proficio Capital Partners LLC now owns 67,600 shares of the medical equipment provider’s stock worth $1,913,000 after acquiring an additional 3,600 shares in the last quarter. 71.02% of the stock is currently owned by institutional investors.

A number of brokerages recently commented on AXGN. ValuEngine upgraded AxoGen from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target (up previously from $37.00) on shares of AxoGen in a research report on Tuesday, May 1st. JMP Securities increased their price target on AxoGen from $34.00 to $43.00 and gave the company a “market outperform” rating in a research report on Tuesday, May 1st. Lake Street Capital set a $38.00 price target on AxoGen and gave the company a “buy” rating in a research report on Friday, March 2nd. Finally, William Blair began coverage on AxoGen in a research report on Monday, February 5th. They issued an “outperform” rating on the stock. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $35.57.

About AxoGen

AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Insider Buying and Selling by Quarter for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply